Nanoform convenes EGM to elect Cynthia Schwalm as board member - Seite 2

Cynthia Schwalm commented, "I have dedicated my career to improving the lives of patients, so Nanoform's ability to advance patient care and disrupt the industry in a positive way impressed me immediately. In my role as board member, I look forward to helping drive forward a company that not only promises to improve efficiency within Pharma, but also change the lives of patients globally by facilitating therapies with fewer side effects and improved delivery."

For further information, please contact:

Prof. Edward Hæggström, CEO

[e-mail] / [phone]

For investor relations queries, please contact:

Henri von Haartman, Director of Investor Relations

[e-mail] / [phone]

Certified Adviser: Danske Bank A/S, Finland Branch, [phone]

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nanoforming services. The Company's patented and scalable Controlled Expansion of Supercritical Solutions (CESS⁾ technology produces nanoformed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Nanoform's unique technology provides novel opportunities in many value-enhancing drug delivery applications.

For more information please visit http://www.nanoform.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nanoform/r/nanoform-convenes-egm-to-elect-cynthia-schwalm-as-board-member,c3164579

The following files are available for download:

https://mb.cision.com/Main/18905/3164579/1287685.pdf

Release